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Abstract
Purpose Patient motion during PET acquisition may affect
measured time-activity curves, thereby reducing accuracy
of tracer kinetic analyses. The aim of the present study was
to evaluate different off-line frame-by-frame methods to
correct patient motion, which is of particular interest when
no optical motion tracking system is available or when
older data sets have to be reanalysed.
Methods Four different motion correction methods were
evaluated. In the first method attenuation-corrected frames
were realigned with the summed image of the first 3 min.
The second method was identical, except that non-
attenuation-corrected images were used. In the third and
fourth methods non-attenuation-corrected images were
realigned with standard and cupped transmission images,
respectively. Two simulation studies were performed, based
on [
11C]flumazenil and (R)-[
11C]PK11195 data sets, re-
spectively. For both simulation studies different types
(rotational, translational) and degrees of motion were
added. Simulated PET scans were corrected for motion
using all correction methods. The optimal method derived
from these simulation studies was used to evaluate two (one
with and one without visible movement) clinical data sets
of [
11C]flumazenil, (R)-[
11C]PK11195 and [
11C]PIB. For
these clinical data sets, the volume of distribution (VT) was
derived using Logan analysis and values were compared
before and after motion correction.
Results For both [
11C]flumazenil and (R)-[
11C]PK11195
simulation studies, optimal results were obtained when
realignment was based on non-attenuation-corrected images.
For the clinical data sets motion disappeared visually after
motion correction. Regional differences of up to 433% in VT
before and after motion correction were found for scans with
visible movement. On the other hand, when no visual motion
was present in the original data set, overall differences in VT
before and after motion correction were <1.5±1.3%.
Conclusion Frame-by-frame motion correction using non-
attenuation-corrected images improves the accuracy of tracer
kinetic analysis compared to non-motion-corrected data.
Keywords PET.Motioncorrection.Kineticmodelling.
Volumeofdistribution
Introduction
Positron emission tomography (PET) is a medical imaging
technique that allows for measurements of tissue function
by following the time course of a tracer labelled with a
positron emitter. Most dynamic brain scans require an
acquisition time of 60–90 min and, for accurate results, the
subject should remain in exactly the same position. In
practice, however, subject motion is not uncommon, espe-
cially not for specific patient groups such as, for example,
patients suffering from Alzheimer’s or Parkinson’s disease.
Full utilisation of improvements in intrinsic spatial
resolution of new PET scanners is increasingly hampered
by patient motion [1]. Patient motion during a PET scan
may reduce effective spatial resolution [2]. More impor-
tantly, patient motion may alter measured time-activity
Electronic supplementary material The online version of this article
(doi:10.1007/s00259-009-1193-y) contains supplementary material,
which is available to authorised users.
J. E. M. Mourik (*):M. Lubberink: F. H. P. van Velden:
A. A. Lammertsma: R. Boellaard
Department of Nuclear Medicine & PET Research,
VU University Medical Center,
P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
e-mail: j.mourik@vumc.nl
Eur J Nucl Med Mol Imaging (2009) 36:2002–2013
DOI 10.1007/s00259-009-1193-ycurves (TAC), especially for small regions of interests (ROI),
therebydirectlyaffectingtheoutcomeoftracerkineticanalysis.
The simplest method to reduce patient motion during
scanning is the use of head restraints. To date, a number of
head restraints are available for reducing motion (e.g. [2,
3]). As these head restraints do not eliminate all move-
ments, even more restrictive head restraints exist that fix the
skull completely [3]. These restrictive head restraints,
however, are very uncomfortable and therefore they are
not used frequently. In addition, many patients (e.g.
traumatic brain injury, obsessive-compulsive disorder) do
not tolerate rigid head fixation.
An alternative is to register motion during scanning
using an optical online motion tracking system. Most recent
optical motion tracking systems [4–6] enable online
correction for motion that occurs within frames (in-frame
patient motion). Online motion tracking systems have two
main advantages. Firstly, when using a motion tracking
system, there is no mismatch between emission and
transmission scans, as emission data are realigned to the
position of the head during the transmission scan. This is
very important, because a mismatch between emission and
transmission scans leads to erroneous attenuation correc-
tion. Secondly, it is possible to correct for in-frame motion,
as realignment may take place several times per second.
However, motion tracking systems also have some dis-
advantages. Firstly, older data sets, acquired prior to
installation of a motion tracking system, cannot be
corrected for patient motion. Secondly, most optical online
motion tracking systems require PET data to be acquired in
list mode, which is not possible on older PET scanners.
Thirdly, online (continuous) motion correction during
reconstruction is not trivial and some difficulties with
normalisation and attenuation correction still need to be
investigated further [7]. Finally, the use of optical (online)
tracking systems is not always possible when the view of
the patient in the gantry is limited. This is, for example, the
case when scanning patients with traumatic brain injury,
where the view within the gantry is partly blocked by
auxiliary equipment, such as that needed for administering
anaesthetics. In those patients, however, motion is observed
frequently.
Frame-by-frame motion correction methods correct
image data post hoc. Existing frame-by-frame methods
use correlation coefficient [8], cross-correlation [9, 10],
mutual information [9, 11], standard deviation of the ratio
of two images [10, 12], sum of absolute differences [10,
12], mean square difference [10], stochastic sign change
[10] or (scaled) least-square difference images [13, 14].
Although, frame-by-frame motion correction methods do
not have the same advantages and performance character-
istics as online (optical) motion tracking systems [11], they
are very useful when no list-mode data are available, when
older data have to be reanalysed or when optical tracking is
not possible because of a limited view into the PET gantry.
The purpose of this study was to evaluate four different
off-line frame-by-frame motion correction methods, previ-
ously introduced by Perruchot et al. [9]. Two of these
motion correction methods in theory also correct for
mismatches between transmission and emission scans.
Methods were evaluated extensively using both simulation
studies and several clinical data sets, covering both tracers
with low and high cerebral uptake.
Materials and methods
Motion correction strategies
This section describes four different motion correction
strategies for multi-frame PET data. These methods differ
in the way realignment parameters were derived.
Method A: AC-on-AC
The simplest motion correction method is based on the
realignment of attenuation-corrected (AC) (standard) PET
images. It is assumed that the first x frames of the AC PET
scan contain no patient motion and therefore the sum of the
first x frames is used as a reference. Frames x+1...N, with N
being the number of frames, are then realigned to this
summed image (Fig. 1a). Using this method, however,
mismatches between emission and transmission scans
remain.
Method B: NAC-on-NAC
Non-attenuation-corrected (NAC) PET images (Fig. 2b, f)
have the advantages, compared to AC PET, that they are
less noisy and that the contours near the skull can be better
distinguished. In theory, NAC images should provide better
realignment than AC images. Again, it is assumed that there
is no patient motion during the first x frames, nor between
transmission scan and start of emission scan. NAC frames
x+1...N are realigned to the sum of the first x NAC frames.
Next, the realigned NAC images are forward projected and
reconstructed. The result of the reconstruction is a realigned
series of AC images. A schematic diagram of method B is
shown in Fig. 1b, where a summed (NAC) image of the
first x frames is used as reference image.
Method C: NAC-on-μ
A disadvantage of both methods A and B is that they do not
correct for a potential mismatch between transmission and
emission scans or for movements during the first x frames.
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tion map (μ-map or μ-image, Fig. 2c, g), reconstructed
from the set of measured attenuation correction factors
(ACF), as reference for realignment. All NAC frames are
then realigned to the μ-map and reconstructed using the
same μ-map for attenuation correction (Fig. 1b, reference
image = μ-image).
Method D: NAC-on-cμ
It has been proposed that a variation of the μ-image, the
cupped μ-image (cμ)[ 9], is better suited for realigning NAC
images, as it has more corresponding contours (Fig. 2d, h).
The cupping effect is obtained as:
mcupped ¼ OSEM ACF

eACF 
All NAC frames are then realigned to the cupped μ-map
and reconstructed using the standard (non-cupped) μ-map
for attenuation correction (Fig. 1b, reference image =
cupped μ-image).
Simulation studies
Simulation studies were used to find optimal settings for the
motion correction strategies. Kind of motion, motion
correction method and definition of reference image were
varied.
Simulated PET scans
Two dynamic PET scans were simulated, each with
different tracer uptake. The first had high cortical tracer
Fig. 1 Overview of the various
motion correction strategies.
a AC-on-AC. b Depending on
reference image: NAC-on-NAC,
NAC-on-μ or NAC-on-cμ. See
text for details
Fig. 2 Examples of a, e attenuation-corrected, b, f non-attenuation-corrected, c, g μ and d, h cupped μ-images for [
11C]flumazenil (a–d) and (R)-
[
11C]PK11195 (e–h) scans
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11C]flumazenil (SIMFMZ).
In contrast, the second had low tracer uptake, simulating a
tracer like (R)-[
11C]PK11195 (SIMPK). Due to its lower
uptake, the latter scan should be more challenging for the
motion correction process. Both simulated PET scans were
based on a grey-white matter segmented MRI scan. For
SIMFMZ, a typical [
11C]flumazenil grey and white matter
TAC was allocated to the grey and white matter segments
of the MRI scan, respectively. SIMPK was generated in the
same way using typical (R)-[
11C]PK11195 grey and white
matter TAC. Simulation scans were noise free and
smoothed with a Gaussian kernel of ∼8 mm full-width at
half-maximum (FWHM) to obtain a spatial resolution compa-
rable to that of regular PET images. SIMFMZ and SIMPK
consisted of 16 and 23 time frames, respectively, identical to
the in-house protocols for clinical studies using these tracers.
Simulated motion
Twotypes ofmotionwere addedtobothsimulatedPETscans.
First, different rotations (3, 4, 5 and 6°, Fig. 3, top row) were
applied, simulating the ‘napping effect’ at the end of a scan.
These rotational movements correspond to movements of
maximum 6.8, 8.2, 9.6 and 11 mm, respectively. The second
type of motion simulated axial movements (2, 4, 6, 10 and
20 mm, Fig. 3, bottom row) of a subject. This movement is
seen most frequently in clinical practice when subjects are
fixed using a head holder. Motion was added using Vinci
software (Max Planck Institute for Neurological Research,
Cologne, Germany, http://www.mpifnf.de/vinci/). Both rota-
tions and translations were simulated as gradual motions
towards the end of the scans, reaching maximum movements
in the final frames.
To assess the effect of motion correction when no
motion is present, an additional simulation study was
performed. This simulation study consisted of 100
motion-free [
11C]flumazenil dynamic PET scans. Random
noise (∼ 8% per pixel) was added to all simulated PET
scans to determine the effect of applying motion correction
on motion-free data on accuracy and precision of VT.
Motion correction
Automated Image Registration (AIR, version 5.1.5; [15])
was used to realign the simulated PET images. For the
present simulation, the 3-D rigid body model using six
parameters was used. Prior to the motion correction
simulation all (original) images were generated with a
clinically relevant spatial resolution of about 8 mm FWHM,
as mentioned before. Both the reference image and the
images to be aligned were additionally smoothed with a
Gaussian kernel of 5 mm FWHM to suppress noise and to
speed up realignment (default AIR settings for moderately
noisy images). This additional smoothing was applied
during the realignment process only in order to obtain the
realignment matrix. The realignment matrix was then
applied to the original image data (at the clinical image
resolution). Thresholds of reference and to be aligned
images were varied. Three different cost functions [16]
were used, namely (1) standard deviation of ratio image, (2)
least squares and (3) least squares with intensity rescaling
(adding an intensity scaling term to the model).
Reference image
A reference image was used for motion correction strategies
A and B. These reference images are based on the sum of
the first x frames of AC PET (method A) or NAC PET
(method B). To find optimal settings for the reference
image, x was varied from 3 to 10, corresponding to a
Fig. 3 Different types of motion added to the original simulated [
11C]
flumazenil PET images (a). The top row (b–e) shows rotational
movements of 3, 4, 5 and 6°, respectively, and the lower row (f–j)
axial translational movements of 2, 4, 6 10 and 20 mm, respectively.
The light grey contour on top of each image corresponds to the
original image (a)
Eur J Nucl Med Mol Imaging (2009) 36:2002–2013 2005summation of the first 45 s to 10 min for SIMFLU and of the
first 30 s to 5 min for SIMPK.
Clinical data
Clinical [
11C]flumazenil, (R)-[
11C]PK11195 and [
11C]PIB
data were used to assess the simulation results in practice.
For all tracers, one subject with large (> 10 mm) and one
with no or minor (< 3 mm) movement were selected. For all
subjects, the maximal amount of, location of and direction of
motion were determined using Vinci software and can be
found in Table 1.[
11C]flumazenil and (R)-[
11C]PK11195
data were corrected for motion using the optimal setting for
SIMFMZ and SIMPK, respectively. [
11C]PIB data were added
as an additional data set to further assess the robustness of
the motion correction method. As [
11C]PIB is a cortical
tracer similar to [
11C]flumazenil, it was corrected for motion
using the optimal settings found for SIMFMZ.
All data were taken from clinical study protocols that
had been approved by the Medical Ethics Review Com-
mittee of the VU University Medical Center. All subjects
had given their informed consent prior to scanning.
All scans were acquired using an ECAT EXACT HR+
scanner (CTI/Siemens, Knoxville, TN, USA). Before tracer
administration, a 10-min transmission scan was acquired in
2-D mode using rotating
68Ge/
68Ga sources. This transmis-
sion scan was used to correct the subsequent emission scan
for attenuation. Subsequently, a dynamic emission scan was
acquired in 3-D acquisition mode following bolus injection.
Scan duration and frame definition differed per tracer, as
described previously [17, 18]. During the emission scan the
arterial input function was measured using a continuous
flow-through blood sampling device [19]. At set times [17,
18], continuous withdrawal was interrupted briefly for
collection of manual samples and, after each sample, the
arterial line was flushed with heparinised saline. These
manual samples were used for calibrating the (online) blood
sampler, for measuring plasma/whole blood ratios and for
determining plasma metabolite fractions.
Axial, coronal and sagittal movies were generated for all
scans (e.g. see supplementary movies S1 and S2). Each
frame of the movie contained a snapshot of the mid-plane
of the PET frame, resulting in a movie of N frames. These
movies were used to visualise patient motion between
frames. To assist visualisation of movements, the edge of
the reference image was projected onto all frames of the
movie (e.g. light grey line in Fig. 3). Note that these movies
were only used to qualitatively visualise patient motion and
that they were not used within the motion correction
methods themselves.
Reconstruction settings
Simulation study
Simulation data were reconstructed using normalisation and
attenuation-weighted ordered subsets expectation maximi-
sation (NAW-OSEM) to obtain AC PET images. In
addition, to obtain NAC PET images, the simulation data
were reconstructed using normalisation-weighted OSEM.
After realignment, these images were forward projected and
then reconstructed using an attenuation-weighted OSEM
algorithm. All reconstructions for the simulation study were
performed using 4 iterations and 18 subsets and consisted
of 63 planes of 128×128 voxels and a voxel size of 2.57×
2.57×2.43 mm
3, identical to the clinical data sets men-
tioned below.
Clinical data
All data were normalised and corrected for attenuation,
random coincidences, scattered radiation, dead time and
decay and reconstructed using NAW-OSEM (2 iterations,
16 subsets), as implemented in the standard ECAT 7.2
software (CTI/Siemens, Knoxville, TN, USA), and after-
wards smoothed with a Gaussian kernel of 5 mm resulting
in an image resolution of 7 mm FWHM. All reconstructed
images consisted of 63 planes of 256×256 voxels of 1.29×
1.29×2.43 mm
3, which were rebinned into 63 planes of
128×128 voxels of 2.57×2.57×2.43 mm
3. In the realign-
ment process, image reconstruction was based on an
identical reconstruction method developed in-house.
Analysis
Simulation study
All simulated data were realigned using the above-
mentioned motion correction strategies. ROIs were drawn
on corresponding SIMFLU or SIMPK T1-weighted MRI
Tracer Maximum amount of motion Type of motion
[
11C]flumazenil ∼11 mm Mainly rotational
(R)-[
11C]PK11195 ∼21 mm Mainly translation in z direction
[
11C]PIB ∼33 mm Rotation + translation in z direction
Table 1 Maximum amount and
type of motion for the largest
movement (clinical data sets)
2006 Eur J Nucl Med Mol Imaging (2009) 36:2002–2013images over different anatomical regions (frontal lobe, pre-
frontal lobe, parietal lobe, thalamus, temporal, occipital,
thalamus, pons, cerebellum, caudate and putamen) using
DISPLAY software (Montreal Neurological Institute, http://
www.bic.mni.mcgill.ca/software/Display/Display.html).
ROIs were projected onto all frames of the simulated PET
scans and TACs were generated as the time sequences of
average ROI values. For all anatomical regions, TACs of
realigned simulated PET scans were compared with the
original (no motion) simulated PET scans. Optimal settings
for the simulation study were determined by finding the
best combination (method, cost function, reference image
generation, etc.) for which differences between regional
activity concentrations after motion correction and the true
(simulated) activity concentrations were minimal.
Parametric volume of distribution (VT) images were
calculated for all (corrected) simulated PET scans using
Logan analysis [20]. Mean VT values for the various
anatomical regions (see above) were calculated and
compared with the corresponding original VT values.
To determine the effect of motion correction on accuracy
and precision of VT with no actual motion present in the
data, 100 motion-free simulated PET scans with added
noise were analysed both with and without motion
correction. Parametric VT images and mean VT values for
various anatomical regions (see above) were calculated. In
addition, per anatomical region, the coefficient of variation
(COV, precision) and bias (accuracy) was calculated. The
COV (%) was calculated as the standard deviation divided
by the mean times 100%. The bias was calculated as the
percentage of change in regional VT values between
motion-free simulated PET scans, which were corrected
for motion, and the original motion-free simulated PET
scans.
Clinical data
All clinical data were realigned using the optimal
settings from the simulation study. The result of each
realignment was evaluated visually by generating three
movies (axial, coronal and sagittal), as described above.
VT images were calculated for both motion-corrected and
uncorrected PET images. Ratio images were generated by
dividing the VT image of the motion-corrected data set by
the VT image of the original (uncorrected) data set. Using
the software package DISPLAY, a total of 15 ROIs were
drawn manually on individually co-registered T1-
weighted MRI images in the same anatomical regions as
specified above. MRI scans were co-registered to summed
images of the first 3 min of the dynamic PET scans. ROIs
were projected onto VT images and mean regional VT
values of uncorrected and motion-corrected TACs were
compared.
Results
Simulations
Effect of motion on TAC
TACs of putamen and parietal cortex for SIMFMZ scans
without and with added motion are shown in Fig. 4a and b,
respectively. Especially for 20-mm translations, differences
in parietal lobe TACs were very large (up to 98%).
Effect of motion on VT
The effects of motion on VT values for different anatomical
regions are shown in Fig. 5. Addition of motion to SIMFMZ
(Fig. 5, black symbols) resulted in lower VT values for all
regions (up to −45.6%), except for pons (maximal +13.1%).
For SIMPK (Fig. 5, orange symbols), higher VT values were
found for pre-frontal regions (maximal +20.8%) and lower
VT values for all other regions (maximal −45.3%).
Parametric VT images of SIMFMZ without and with 20-
mm translation are shown in Fig. 6a and b, respectively. It
Fig. 4 TACs of a putamen and b parietal cortex for SIMFMZ scans
without and with various degrees of movement (3 and 6° rotation, 4
and 20 mm translation)
Eur J Nucl Med Mol Imaging (2009) 36:2002–2013 2007can be seen that there are large differences between the two
images. In addition, there are clear artefacts in the image
after translation (Fig. 6b), which are highlighted in the ratio
of both images (Fig. 6d).
Optimal motion correction method
Optimal setting for both SIMFMZ and SIMPK are listed in
Table 2.F i g u r e7a and b show differences between VT
values before and after motion correction for SIMFMZ and
SIMPK, respectively, using the optimal combination of
settings found in the simulation study (cost function,
number of summed frames and thresholds) for each
motion correction strategy. For both simulation studies,
best results were obtained using motion correction
strategy B (NAC-on-NAC). Using this method, for
SIMFMZ, maximal differences in VT values (Fig. 7a,r e d
symbols) were found for pons (< 2.7%) and putamen
(< 2.8%). For SIMPK, the largest differences in VT values
(Fig. 7b, red symbols) were found for pre-frontal cortex
(< 3.3%) and pons (< 3.5%). When no motion was added,
no significant differences (p>0.20) were found between
SIMFMZ before and after motion correction, and minimal
effects on accuracy and precision of VT were found
(Table 3). For SIMPK slightly lower (pons: −3.4%) VT
values were found after motion correction, but these
values were not significantly different from the original
ones (p>0.22).
Fig. 5 Differences (%) in VT
values between original (no
motion) simulated PET data and
corresponding PET data after
adding motion for SIMFMZ
(black symbols) and SIMPK
(orange symbols)
Fig. 6 Parametric VT images of
simulation study. a VT of origi-
nal (no motion) SIMFMZ. b VT
of SIMFMZ after adding 20-mm
translation. c As b but after
motion correction. d Ratio im-
age of a and b. e Ratio image of
a and c. Note that the range of
the colour scale of d and e is
different
2008 Eur J Nucl Med Mol Imaging (2009) 36:2002–2013Figure 6c shows a VT image after motion correction
using the optimal settings. The artefacts, as visible on the
motion-affected VT image (Fig. 6b), have completely
disappeared. The ratio image between the original VT
image (Fig. 6a) and the motion-corrected VT image
(Fig. 6c) is shown in Fig. 6e. As can be seen, only small
differences between original VT and motion-corrected VT
image were found.
Clinical data
Large movements
Using frame-by-frame movies, all clinical data were inspected
for motion visually (supplementary movies S1 and S2). Using
this method, no motion could be detected after application of
the motion correction algorithm. Figure 8 shows parametric
VT images before and after motion correction, together with
corresponding MRI images, for data sets with large move-
ments. For [
11C]flumazenil, no large differences between VT
images before and after motion correction can be detected
visually. Nevertheless, the ratio image showed significant
differences (Fig. 8, top row, last column). At a regional level,
the largest differences between VT values before and after
motion correction were found for the parietal lobe (26.9%).
For [
11C]flumazenil, the difference between VT before and
after motion correction across all anatomical regions was on
average 8.3±8.1%. A sagittal animation of the original [
11C]
flumazenil data set and the realigned [
11C]flumazenil data set
is shown in supplementary movie S1.
For both (R)-[
11C]PK11195 (Fig. 8, middle row) and
[
11C]PIB (Fig. 8, bottom row), major differences were seen
between VT images before and after motion correction with
large artefacts in the uncorrected VT image. The large
difference between original and corrected images is also
clearly visible in the ratio image of both VT images (Fig. 8,
middle row, last column). For [
11C]PIB, differences were
even more pronounced (Fig. 8, bottom row). At a regional
level quantitative differences were as high as 433% (right
thalamus). Across all regions, the average difference was
85±121%. Supplementary movie S2 shows the original
[
11C]PIB data set and the [
11C]PIB data set after motion
correction. Quantitative differences for (R)-[
11C]PK11195
were smaller, with a maximum of 49% (parietal lobe) and
an average (across all anatomical regions) of 14.9±15.1%.
Minor movements
Parametric VT images before and after motion correction,
together with corresponding MRI images, for data sets with
no or minor movements are shown in Fig. 9. No visual
differences between images before and after motion
correction could be seen. However, for [
11C]flumazenil
(Fig. 9, top row), the ratio image suggests that there was
some (small) motion present in the original data set. For
[
11C]flumazenil, the largest difference at regional level was
Table 2 Optimal settings for both simulation studies
Simulation Optimal method Cost function Threshold of aligned frames Threshold of reference frame Sum frames
SIMFMZ NAC-on-NAC LS 0% MPV 0% MPV 1–6( 0 –3 min)
SIMPK NAC-on-NAC LSIR 40% MPV 35% MPV 1–8( 0 –3 min)
LS least squares, LSIR least squares with intensity rescaling, % MPV percentage of maximum pixel value
Fig. 7 Differences (%) in VT between simulated PET scans without
and with added motion following motion correction for a SIMFMZ and
b SIMPK using AC-on-AC (blue symbols), NAC-on-NAC (red
symbols), NAC-on-μ realign (green symbols) and NAC-on-cμ realign
(light blue symbols)
Eur J Nucl Med Mol Imaging (2009) 36:2002–2013 2009found for right caudate (10.9%), but averaged over all
regions differences were only 3.6±3.8%. For both (R)-[
11C]
PK11195 (Fig. 9, middle row) and [
11C]PIB (Fig. 9, bottom
row), only small differences were found (max. 4.3%). On
average, over all regions, differences between VT before
and after motion correction were 0.4±0.4% and 1.5±1.3%
for (R)-[
11C]PK11195 and [
11C]PIB, respectively.
Discussion
Simulations
The simulation studies showed that motion had a large
impact on both regional TACs (max. 98% for the motion
parameters selected) and parametric tracer kinetic analysis
(max. 45%). Furthermore, these studies showed that the
best motion correction method from a theoretical point of
view, where emission and transmission scans were aligned
(method C or D), did not provide the best results. In fact,
for SIMFMZ these methods gave the poorest results (see
Fig. 7a, green and light blue symbols) and frequently
motion correction failed completely. One reason for these
poor results in the case of SIMFMZ may be that the (cupped)
μ and PET images (either AC or NAC) only have limited
corresponding contours or information (see Fig. 2). Al-
though for SIMPK more corresponding contours or infor-
mation were seen, motion correction still failed frequently,
especially for the last few frames (data not shown).
The best results were obtained for method B, NAC-on-
NAC, which is consistent with a previous study performed
by Perruchot et al. [9]. This method assumes that there is no
motion during the first x minutes. If this assumption holds,
and the patient has not moved between transmission and
COV (%) original COV (%) after realignment Bias (%)
Pre-frontal 0.54 0.57 −0.66
Temporal 0.63 1.04 −0.28
Thalamus 1.04 1.11 −0.53
Pons 0.82 1.15 0.80
Parietal lobe 0.47 0.57 0.38
Putamen 1.09 1.39 −0.19
Table 3 Precision (COV, %)
and bias (accuracy, %) of opti-
mal motion correction method in
cases of motion-free simulated
PET scans
Fig. 8 Differences in VT images generated from clinical PET scans
with large movements before and after motion correction. From left to
right: MRI, parametric VT images before (original) and after motion
correction and ratio image (corrected divided by original) for [
11C]
flumazenil (top row), (R)-[
11C]PK11195 (middle row) and [
11C]PIB
(bottom row)
2010 Eur J Nucl Med Mol Imaging (2009) 36:2002–2013emission scan, emission and transmission scans are aligned.
Using the optimal motion correction strategy B (NAC-on-
NAC), corrected VT values maximally differed by 3.5%
from the original (true) VT values.
Clinical data
Large movements
Both [
11C]flumazenil and (R)-[
11C]PK11195 data sets were
corrected very well using the settings found in the
simulation study. Using frame-by-frame movies and super-
imposing the contour of the first x frames is a useful tool to
determine whether motion is present.
Differences between original VT images and VT images
after motion correction were large (up to 49%). In addition,
large artefacts, present in the original (R)-[
11C]PK11195 VT
images, disappeared when motion correction was applied.
Artefacts were less visible in the original [
11C]flumazenil
VT images, which is caused by the particular distribution of
activity together with the smaller amount of motion in the
[
11C]flumazenil data set (Table 1). Although visually there
was close agreement between VT images before and after
motion correction, both ratio image and ROI analysis
showed that the effects of motion were considerable with
differences at a regional level being as high as 26.9%.
Therefore, it is recommended that all data be inspected for
the presence of motion, e.g. by visual inspection of frame-
by-frame movies. In addition, results of the present study
indicate that motion correction could always be applied, as
effects in case of minor movements are small.
Minor movements
Although the simulation studies already showed that, in the
absence of movement, there were no significant changes in
VT values, minor movements were further evaluated for
three clinical data sets. Only for the [
11C]flumazenil study
were small changes in VT after motion correction observed.
This suggests that there was some small movement,
although it cannot be excluded that the change was due to
the correction algorithm itself. The latter is, however,
unlikely as changes for both (R)-[
11C]PK11195 and [
11C]
PIB were very small (max. 1.5±1.3%). These results
confirmed those of the simulation studies in that corrections
were negligible for minor movements.
Limitations
One limitation of the proposed frame-by-frame motion
correction method is its vulnerability to the quality of the
scan data and noise characteristics [4]. Montgomery et al.
Fig. 9 Differences in VT images generated from clinical PET scans
with no or minor movements before and after motion correction. From
left to right: MRI, parametric VT images before (original) and after
motion correction and ratio image (corrected divided by original) for
[
11C]flumazenil (top row), (R)-[
11C]PK11195 (middle row) and [
11C]
PIB (bottom row)
Eur J Nucl Med Mol Imaging (2009) 36:2002–2013 2011[11] claimed that problems may occur within the last frame
of the PET scan because of poor statistics. This may
especially be the case for older data sets acquired on lower
sensitivity scanners. In the present study, effects of noise
were reduced as much as possible by reconstructing data
sets with OSEM, which provides images with less noise
then filtered back projection. In addition, images were
smoothed (only) during the motion correction process,
which was not only helpful for the motion correction
optimisation process, but also for reducing the level of
noise. Problems with the last frame, as reported by
Montgomery et al. [11], were not observed in the present
study. Although it is possible that the motion correction
algorithm might fail due to low image quality, this does not
seem to be likely given the positive results with the low
uptake ligand (R)-[
11C]PK11195 in the present study.
Another limitation of the frame-by-frame motion correc-
tion method is the underlying assumption that there is no
significant change in activity distribution within and
between frames [4]. This assumption can only be true for
the last frames. In fact, the activity distribution varies
rapidly in the first frames. For the optimal motion
correction method B, the summed reference image has
therefore another activity distribution compared to the later
frames. However, for the present study, this did not cause
any problems during the motion correction process.
The optimal motion correction method derived from the
present study assumes that there is no mismatch between
the transmission scan and the first x frames of the emission
scan. This is a reasonable assumption, because most patient
motion appears at later time points of the scan (>10 min)
(data not shown). It is, however, recommended that correct
alignment of transmission and early (in this case 0–3 min
post-injection) emission scans be verified. Nevertheless, if
motion appears between transmission and emission scan or
within the first 3 min of the emission scan, the mismatch
between transmission and emission scans remains. Al-
though motion correction methods C and D correct for
emission and transmission mismatch, no satisfactory results
were obtained in this study. The use of different cost
functions might improve the performance of these methods
and therefore have to be investigated. However, for some
tracers, like [
11C]flumazenil with high cortical uptake,
methods C and D will probably always fail because there
is too little commonality between the emission (NAC) and
µ-images. Even if a mismatch between emission and
transmission scans would exist, results of the present study
show that a frame-by-frame correction method provides a
major improvement in accuracy of pharmacokinetic analy-
ses over non-motion-corrected data.
As mentioned before, the final method derived from the
present study does not correct for in-frame motion and
therefore motion could still be present within a frame.
However, the present method may be suited to identify
suspicious frames and exclude those frames in the
following analysis. An easy way to do this is to make a
frame-by-frame movie of a data set and identify in which
frame the motion starts. Subsequently, the frames before
and after the initial motion-affected frame should be
visually inspected for any unexpected blurring. A highly
blurred frame indicates that there is considerable patient
motion during the frame and therefore that frame should be
excluded in further analysis.
The AIR package was chosen because it is freely
available, easily adjustable and fast. However, it has the
disadvantage that only three different cost functions are
available. In some applications other cost functions, such as
those based on mutual information, may be more appropri-
ate. In those cases, however, it will be necessary to again
determine optimal settings for that specific registration
algorithm.
Clinical applicability
The present study shows that it is possible to perform
an accurate off-line motion correction for dynamic brain
studies. In theory, this method should also be applicable
to other organs, provided observed motions are rigid.
The latter requirement, however, will limit use of the
proposed method for non-brain studies. Even when
the method would be applicable, optimal settings for
the motion correction algorithm need to be re-evaluated
f o rs u c ha na p p l i c a t i o n .
For older data sets, no raw data may be available. The
optimal method presented here does not require sinogram
or list-mode data, but only reconstructed PET and µ-
images. Therefore, this method can also be used for
accurate motion correction of older data sets.
In clinical practice, subjects are fixed using a head
holder. The movements that are most frequently observed
are rotations around the x-axis and axial translations.
Therefore, only these kinds of movements were included
in the simulation study. Clearly, other types of motion (e.g.
rotations around the z-axis) may also occur. It should be
noted, however, that these types of motion will also be
corrected for using the method presented, as all rotational
and translational movements are obtained during the
registration process.
Conclusion
If no optical tracking system is available or when older data
sets need to be reanalysed, a frame-by-frame motion
correction method, based on non-attenuation-corrected
images, provides major improvements in accuracy of
pharmacokinetic analyses over non-motion-corrected data.
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